Nomura Holdings Inc vs Health Care Select Sector SPDR Fund — how do they compare? Nomura Holdings Inc trades at $9.86 (market cap $28.69B), while Health Care Select Sector SPDR Fund trades at $168.03. The key difference: Nomura Holdings Inc pays a 3.3% dividend while Health Care Select Sector SPDR Fund pays none. Which is the better fit depends on your goals.
| NMR | XLV | |
|---|---|---|
Market Cap | $28.69B | — |
Sector | Financials | — |
52-Week High | $10.04 | $168.44 |
52-Week Low | $6.73 | $130.29 |
Dividend Yield | 3.3% | — |
Signals from Pluang's Aura AI — not financial advice
Nomura Holdings (NMR) trades at $9.95, up 0.3% on the day, with a bullish technical signal from moving averages. The stock shows strong fundamentals, including a P/E of 11.77 and net income margin of 20.4%, supported by record annual profit in 2025. Recent Q2 2026 earnings beat expectations, and revenue growth trends upward, though cash flow from operations remains negative.
Outlook is positive with valuation appeal and earnings momentum, but risks include volatile cash flows, high debt levels, and reliance on wholesale revenue. Analysts are mixed, with 33% buy ratings. The stock presents a value opportunity amid bullish technicals, yet investors should weigh debt concerns against growth prospects.
XLV trades at $165.68, up 0.75% with a bullish technical signal from moving averages. The healthcare ETF shows strong defensive positioning amid market volatility, with recent articles highlighting its cost efficiency at 0.08% expense ratio and $41.7 billion AUM. Technical indicators show support at $164 and resistance at $167, with RSI levels in neutral territory suggesting balanced momentum.
The outlook remains positive given healthcare's defensive characteristics and recent sector inflows. Key risks include regulatory pressures and competitive ETF offerings, but XLV's diversification across 60 healthcare stocks provides stability. Analyst comparisons favor XLV for lower costs and steady performance versus specialized biotech ETFs.
Trailing returns across standard periods
Latest headlines on both assets
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →